🇺🇸 FDA
Pipeline program

Uplizna 100 mg concentrate for solution for infusion

20240236

Phase 2 small_molecule active

Quick answer

Uplizna 100 mg concentrate for solution for infusion for Generalized Myasthenia Gravis is a Phase 2 program (small_molecule) at Amgen Technology (Ireland) UC with 1 ClinicalTrials.gov record(s).

Program details

Company
Amgen Technology (Ireland) UC
Indication
Generalized Myasthenia Gravis
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials